Virender Kumar Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Virender Kumar Pal has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amit Singh
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India
3 shared publications - Agnes-Laurence Chenine
Integrated BioTherapeutics Inc., 4 Research Court, Suite 300, Rockville, MD 20850, USA
2 shared publications - Bobban Subhadra
BIOM Pharmaceutical Corporation, Sarasota, FL 34234, USA
2 shared publications - Jeffy George Mattathil
Integrated BioTherapeutics Inc., 4 Research Court, Suite 300, Rockville, MD 20850, USA
2 shared publications - Ragini Agrawal
Department of Microbiology and Cell Biology, Center for Infectious Disease Research, Indian Institute of Science (IISc), CV Raman Ave., Bengaluru 560012, India
2 shared publications - Govindasamy Mugesh
Department of Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore 560012, India
1 shared publication
Latest Publications
- Open Access
Reply to Kulić, Ž. Comment on “Subhadra et al. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. Viruses 2023, 15, 1299”
We would like to thank Dr. Žarko Kulić
Open AccessReply to Kulić, Ž. Comment on “Subhadra et al. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. Viruses 2023, 15, 1299”
We would like to thank Dr. Žarko Kulić
- Open Access
Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.
Open AccessSignificant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.
- Open Access
Antioxidant nanozyme counteracts HIV-1 by modulating intracellular redox potential
Reactive oxygen species (ROS) regulates the proliferation of human immunodeficiency virus (HIV-1) and Mycobacterium tuberculosis ( Mtb ) inside the infected immune cells. However, the application of this knowledge to develop therapeutic strategies remained unsuccessful due to unfavorable consequences of manipulating cellular antioxidant systems that respond to ROS. Here, we show that vanadium pentoxide (V 2 O 5 ) nanosheets functionally mimic the activity of natural glutathione peroxidase (GPX) to mitigate ROS associated with HIV-1 infection without triggering detrimental changes in cellular physiology. Using genetic reporters of glutathione (GSH) redox potential ( E GSH ; Grx1-roGFP2) and H 2 O 2 (Orp1-roGFP2), we showed that V 2 O 5 -nanosheets catalyze GSH-dependent neutralization of ROS in HIV-1 infected cells. Notably, V 2 O 5 -nanosheets uniformly blocked HIV-1 reactivation, multiplication, and impaired survival of drug-resistant Mtb during HIV-TB co-infection. Mechanistically, V 2 O 5 -nanosheets suppressed HIV-1 by affecting the expression of pathways coordinating redox balance, virus transactivation ( e.g., NF-κB and FOS), inflammation, and apoptosis. Importantly, a combination of V 2 O 5 -nanosheets with a pharmacological inhibitor of NF-κB (BAY11-7082) abrogated activation of HIV-1 from latency. Lastly, V 2 O 5 -nanosheets counteracted ROS, disease pathophysiology, and virus expression in HIV-1 transgenic mice. Our data successfully revealed the usefulness of V 2 O 5 -nanosheets against human pathogens and suggest nanozymes as future platforms to develop interventions against infectious diseases. Significance Statement: Redox stress, such as those caused by the deregulation of the antioxidant glutathione, promotes the multiplication of human immunodeficiency virus-1 (HIV-1) and Mycobacterium tuberculosis ( Mtb ). Here we present a vanadium pentoxide (V 2 O 5 )-based antioxidant nanozyme that targets cells infected with HIV-1. The nanozyme, by mimicking the activity of glutathione peroxidase, reprograms redox signaling to subvert HIV-1 from monocytes, lymphocytes, and HIV-1 transgenic mice. Treatment with nanozyme bolsters the antiviral potential of immune cells by reducing the expression of genes involved in virus activation, inflammation, and apoptosis. The nanozyme also inhibited the proliferation of Mtb , which is a major cause of lethality in HIV patients. These V 2 O 5 -based nanozymes may be applied to numerous human pathogens where redox signaling contributes to disease progression.
Open AccessAntioxidant nanozyme counteracts HIV-1 by modulating intracellular redox potential
Reactive oxygen species (ROS) regulates the proliferation of human immunodeficiency virus (HIV-1) and Mycobacterium tuberculosis ( Mtb ) inside the infected immune cells. However, the application of this knowledge to develop therapeutic strategies remained unsuccessful due to unfavorable consequences of manipulating cellular antioxidant systems that respond to ROS. Here, we show that vanadium pentoxide (V 2 O 5 ) nanosheets functionally mimic the activity of natural glutathione peroxidase (GPX) to mitigate ROS associated with HIV-1 infection without triggering detrimental changes in cellular physiology. Using genetic reporters of glutathione (GSH) redox potential ( E GSH ; Grx1-roGFP2) and H 2 O 2 (Orp1-roGFP2), we showed that V 2 O 5 -nanosheets catalyze GSH-dependent neutralization of ROS in HIV-1 infected cells. Notably, V 2 O 5 -nanosheets uniformly blocked HIV-1 reactivation, multiplication, and impaired survival of drug-resistant Mtb during HIV-TB co-infection. Mechanistically, V 2 O 5 -nanosheets suppressed HIV-1 by affecting the expression of pathways coordinating redox balance, virus transactivation ( e.g., NF-κB and FOS), inflammation, and apoptosis. Importantly, a combination of V 2 O 5 -nanosheets with a pharmacological inhibitor of NF-κB (BAY11-7082) abrogated activation of HIV-1 from latency. Lastly, V 2 O 5 -nanosheets counteracted ROS, disease pathophysiology, and virus expression in HIV-1 transgenic mice. Our data successfully revealed the usefulness of V 2 O 5 -nanosheets against human pathogens and suggest nanozymes as future platforms to develop interventions against infectious diseases. Significance Statement: Redox stress, such as those caused by the deregulation of the antioxidant glutathione, promotes the multiplication of human immunodeficiency virus-1 (HIV-1) and Mycobacterium tuberculosis ( Mtb ). Here we present a vanadium pentoxide (V 2 O 5 )-based antioxidant nanozyme that targets cells infected with HIV-1. The nanozyme, by mimicking the activity of glutathione peroxidase, reprograms redox signaling to subvert HIV-1 from monocytes, lymphocytes, and HIV-1 transgenic mice. Treatment with nanozyme bolsters the antiviral potential of immune cells by reducing the expression of genes involved in virus activation, inflammation, and apoptosis. The nanozyme also inhibited the proliferation of Mtb , which is a major cause of lethality in HIV patients. These V 2 O 5 -based nanozymes may be applied to numerous human pathogens where redox signaling contributes to disease progression.